Home › Therapeutic areas › Oncology › Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer (40 companies)
Companies with an active program in Non-Small Cell Lung Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $69.0M | 9 |
| AKTS | Aktis Oncology | Oncology | 2 | Phase 1 | $880M | 10 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 1 | Phase 3 | $2.63B | 8 |
| BDTX | Black Diamond Therapeutics | Oncology | 2 | Phase 2 | $99.7M | 4 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 2 | Phase 1 | $164M | 6 |
| CCCC | C4 Therapeutics | Oncology | 1 | Phase 2 | $407M | 2 |
| CADL | Candel Therapeutics | Oncology | 1 | Phase 3 | $670M | 4 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | $186M | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $503M | 10 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $728M | 10 |
| EIKN | Eikon Therapeutics | Oncology | 1 | Phase 2 | $320M | 13 |
| ERAS | Erasca | Oncology | 1 | Phase 1 | $5.04B | 5 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $17.0B | 23 |
| GNLX | Genelux | Oncology | 1 | Phase 3 | $88.7M | 3 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | $3.02B | 14 |
| IMTX | Immatics | Oncology | 2 | Phase 3 | $968M | 8 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | $238M | 5 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $9.15B | 16 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.60B | 15 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.13B | 9 |
| INBX | Inhibrx Biosciences | Oncology | 1 | NDA Submitted | $1.24B | 6 |
| KAPA | Kairos Pharma | Oncology | 3 | Phase 2 | — | 13 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 1 | Phase 2 | $82.0M | 13 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $647M | 12 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $64.5M | 7 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.27B | 11 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | $106M | 7 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.67B | 13 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 2 | Phase 3 | $719M | 9 |
| ORIC | Oric Pharmaceuticals | Oncology | 1 | Phase 3 | $914M | 5 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $67.4M | 7 |
| RVMD | Revolution Medicines | Oncology | 3 | Approved | $41.6B | 11 |
| SMMT | Summit Therapeutics | Oncology | 1 | NDA Submitted | $13.1B | 6 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 1 | Approved | $852M | 7 |
| TNGX | Tango Therapeutics | Oncology | 2 | Phase 1 | $3.63B | 4 |
| VSTM | Verastem | Oncology | 1 | Approved | $1.06B | 5 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 1 | Phase 3 | $2.09B | 12 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
| ZYME | Zymeworks | OncologyRespiratory | 2 | Approved | $2.10B | 11 |
No companies match.